- MSD invests over €500 million in acquiring WuXi Vaccines' Dundalk site.
- The handover process is expected to complete by the first half of 2025.
- The acquisition will add approximately 1,000 jobs across Ireland.
- The Dundalk facility includes drug substance and product manufacturing.
Acquisition Details
MSD has announced the acquisition of WuXi Vaccines' manufacturing facility in Dundalk, Co Louth, as part of its long-term plans in Ireland. This acquisition represents an investment of over €500 million, following a previous €1 billion investment in Carlow and Dunboyne, Co Meath.
Timeline and Employment Impact
The official handover process between MSD and WuXi Vaccines is set to be completed in the first half of 2025. As part of this acquisition, MSD plans to add approximately 1,000 jobs across its eight locations in Ireland, including counties Carlow, Cork, Dublin, Louth, Meath, and Tipperary.
Facility Specifications
The Dundalk site is a 15,520-square-meter, three-story vaccine manufacturing facility. It includes drug substance manufacturing, drug product manufacturing, and quality control labs, currently employing around 200 professionals. The facility will supply vaccine products for the global market.
Strategic Importance
This acquisition underscores the successful collaboration between MSD and WuXi Vaccines, which began in 2019. It also highlights Ireland's position as a leader in the pharmaceutical value chain, attracting significant investments from global companies.
```